GDP (gemcitabine, dexamethasone, cisplatin) salvage therapy results in superior progression free survival compared to mini-beam prior to autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma.

被引：1
|
作者：
Kuruvilla, J [1 ]
Nagy, T [1 ]
Pintilie, M [1 ]
Keating, A [1 ]
Crump, M [1 ]
机构：
[1] Univ Toronto, Princess Margaret Hosp, Blood & Marrow Transplant Program, Toronto, ON, Canada
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
10.1182/blood.V104.11.905.905
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
905
引用
收藏
页码：258A / 259A
页数：2
相关论文
共 50 条
  • [1] Gemcitabine, dexamethasone and cisplatin (GDP) salvage chemotherapy is a dominant economic strategy when compared to mini-beam pre-autologous stem cell transplantation (ASCT) for relapsed or refractory Hodgkin's lymphoma
    Kuruvilla, J
    Cavalcanti, R
    Keating, A
    Crump, M
    ANNALS OF ONCOLOGY, 2005, 16 : 214 - 214
  • [2] Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral brood stem cell transplantation
    Fernández-Jiménez, MC
    Canales, MA
    Ojeda, E
    de Bustos, JG
    Aguado, MJ
    Hernández-Navarro, F
    HAEMATOLOGICA, 1999, 84 (11) : 1007 - 1011
  • [3] Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma
    Kuruvilla, J
    Nagy, T
    Pintilie, M
    Tsang, R
    Keating, A
    Crump, M
    CANCER, 2006, 106 (02) : 353 - 360
  • [4] Gemcitabine, dexamethasone, and cisplatin (GDP) as an effective therapy as salvage and mobilization regimen in patients with relapsed or refractory Hodgkin lymphoma.
    Gokmen, Ayla
    Soydan, Ender
    Gokgoz, Zafer
    Kurdal, Mevlude
    Tek, Ibrahim
    Ilhan, Osman
    Arslan, Onder
    Ozcan, Muhit
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation
    Girouard, C
    Dufresne, J
    Imrie, K
    Stewart, AK
    Brandwein, J
    Prince, HM
    Pantolony, D
    Keating, A
    Crump, M
    ANNALS OF ONCOLOGY, 1997, 8 (07) : 675 - 680
  • [6] GEMCITABINE, DEXAMETHASONE, AND CISPLATIN (GDP): EFFECTIVE AND WELL-TOLERATED SALVAGE THERAPY FOR RELAPSED/REFRACTORY HODGKIN LYMPHOMA (HL)
    Moccia, A. A.
    Hoskins, P.
    Klasa, R.
    Savage, K. J.
    Shenkier, T.
    Skinnider, B.
    Slack, G.
    Gascoyne, R. D.
    Connors, J. M.
    Sehn, L. H.
    HAEMATOLOGICA, 2010, 95 : S28 - S29
  • [7] Gemcitabine, Cisplatin, and Dexamethasone as a Salvage and Mobilization Chemotherapy Before Autologous Stem Cell Transplantation is Effective and Safe Outpatient Regimen in Relapsed and Refractory Hodgkin Lymphoma Patients
    Gokmen, Ayla
    Sahin, Ugur
    Soydan, Ender
    Gokgoz, Zafer
    Okcu, Mevlude Kurdal
    Ozan, Ulku
    Arslan, Onder
    Ilhan, Osman
    Ozcan, Muhit
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (10): : E885 - E892
  • [8] Outcome of gemcitabine-based salvage chemotherapy and autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma
    Kuruvilla, J.
    Nagy, T.
    Zadeh, S.
    Puig, N.
    Seshadri, T.
    Tsang, R.
    Keating, A.
    Crump, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 77 - 77
  • [9] Gemcitabine, cisplatin and dexamethasone as a salvage and mobilization chemotheraphy before autologous stem-cell transplantation is effective and safe outpatient regimen in relapsed/refractory hodgkin lymphoma patients
    Gokmen, A.
    Sahin, U.
    Soydan, E.
    Kurdal, M.
    Ozan, U.
    Ilhan, O.
    Arslan, O.
    Ozcan, M.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 305 - 305
  • [10] Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma
    Moccia, Alden A.
    Hitz, Felicitas
    Hoskins, Paul
    Klasa, Richard
    Power, Maryse M.
    Savage, Kerry J.
    Shenkier, Tamara
    Shepherd, John D.
    Slack, Graham W.
    Song, Kevin W.
    Gascoyne, Randy D.
    Connors, Joseph M.
    Sehn, Laurie H.
    LEUKEMIA & LYMPHOMA, 2017, 58 (02) : 324 - 332
12345